FDA Guidance Eases Biosimilar Factory Changes for Drug Makers
Published Date: 10/13/2026
Notice
Summary
The FDA just released clear answers for companies making changes to biosimilar medicines after approval. This helps drug makers keep their products safe and effective without delays or extra costs. If you’re involved in biosimilar production, this guidance is your new go-to for smooth updates and staying on track with the rules.
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Final guidance on postapproval changes
If you make biosimilar or interchangeable biosimilar products licensed under section 351(k) of the Public Health Service Act, the FDA published a final guidance (announced October 13, 2026) that answers common questions about postapproval manufacturing changes. The guidance is intended to inform applicants about the nature and type of information to provide for different reporting categories to support those manufacturing changes.
Clarified use of original 351(k) BLA analytical data
The final guidance explicitly clarifies recommendations for leveraging comparative analytical assessment data from an original 351(k) biologics license application (351(k) BLA) when supporting postapproval manufacturing changes. Applicants may rely on specified comparative analytical assessment data from their original 351(k) BLA per the guidance recommendations.
Clarified support for new dosage/strength supplements
FDA clarified edits to Q&A 4 in the guidance about the nature and type of information recommended to support approval of a supplement for a dosage form or a strength that has not previously been licensed under the 351(k) BLA. Applicants submitting supplements for a new dosage form or strength should follow these clarified recommendations.
Supersedes prior Q&A on manufacturing changes
The final guidance supersedes and withdraws Q&A I.20 from the earlier "Questions and Answers on Biosimilar Development and the BPCI Act" guidance. Applicants should follow this standalone guidance instead of Q&A I.20 when addressing postapproval manufacturing changes.
Alignment with ICH Q5E comparability principles
FDA states the final guidance further aligns its recommendations with the International Council for Harmonisation (ICH) guidance Q5E, "Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process" (June 2005). Applicants should consider ICH Q5E principles when preparing information to support manufacturing changes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-20816, Welded Stainless Steel Pressure Pipe From the Socialist Republic of Vietnam: Preliminary Results of and Intent To Rescind, in Part, Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce found that Vietnam sold welded stainless steel pressure pipes at unfairly low prices from July 2024 to June 2025. They plan to stop reviewing seven companies in this case but want feedback before final decisions. This could affect import duties and trade fairness starting October 2026.
Next: 2026-20819, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension: Form N-54C
The SEC is asking to keep using Form N-54C, which lets certain investment companies tell the government when they stop being business development companies. About eight companies a year file this form, spending roughly one hour each, costing around $774 per filing. This extension keeps the process smooth with no big changes or extra costs, so companies can easily update their status when needed.